About BioRegenEx
BioRegenEx is a U.S. distributor of mesenchymal stem cell (MSC)-derived exosomes, supplying licensed physicians, clinics, and researchers for research use only. The material BioRegenEx distributes is manufactured under cGMP-aligned processes in an FDA-registered United States facility, derived from screened Wharton’s Jelly tissue, and released with a third-party Certificate of Analysis on every lot.
BioRegenEx is not a medical practice. The company operates no clinics, employs no treating physicians, administers no therapy, and does not sell to consumers. It is also not the manufacturer. BioRegenEx selects, qualifies, and supplies characterized material to licensed professionals — along with the documentation that describes it.
Why BioRegenEx exists
The regenerative medicine supply market grew faster than its documentation did. By the time most physicians began evaluating exosome products, the category had filled with material sold on particle counts that were never independently verified, from tissue sources that were never disclosed, shipped without temperature control, and described with claims no supplier could substantiate.
The practical result was that a physician had no reliable way to compare two vials.
BioRegenEx exists to answer a narrower and more answerable question: what would it take for a physician to know exactly what is in the vial, where it came from, and how it was tested? Everything below follows from that — independent lot testing rather than in-house numbers, a single disclosed tissue source rather than a blend, cold-chain custody, and a published research library that links to primary literature rather than summarizing it.
What BioRegenEx verifies before material ships
Four questions decide whether an exosome product is worth a physician’s trust. Most suppliers answer none of them.
What is actually in the vial? Every lot is characterized before release: particle count and size distribution by nanoparticle tracking analysis (NTA), exosome identity markers CD9, CD63 and CD81 confirmed, plus sterility, mycoplasma screening, and endotoxin by LAL assay. Results are issued on a Certificate of Analysis by an independent laboratory — not self-reported.
Where did the source tissue come from? Wharton’s Jelly from donated, consented full-term umbilical cord tissue, screened before use. A single disclosed source — not a blend, and not described vaguely as “perinatal.” No embryonic material is involved.
How is it handled? Temperature-controlled logistics from facility to delivery. Sterile saline vials are stable at −80 °C for 18 months, or in a standard freezer for up to 3 months. Storage requirements are stated plainly, because a product mishandled on arrival is not the product that was tested.
What does the evidence actually show? BioRegenEx maintains an indexed library of 229 peer-reviewed studies, with human clinical studies listed first and every entry linked to PubMed or DOI — including studies reporting null and mixed results.
Material specifications
Published because they can be checked. A supplier unwilling to state these numbers is asking to be taken on faith.
| Source tissue | Wharton’s Jelly, donated full-term umbilical cord, screened and consented donors |
|---|---|
| Vesicle size range | 30–200 nm |
| Concentration standard | 20 billion exosomes per mL |
| Sterile saline vials | 20B / 40B / 100B particles |
| Topical formulations | 100B / 200B particles |
| Identity markers | CD9, CD63, CD81 — confirmed per lot |
| Particle characterization | Nanoparticle tracking analysis (NTA) on every production batch |
| Lot release testing | Sterility · mycoplasma screening · endotoxin (LAL) · particle size distribution |
| Formulation | No xenobiotic components · phenol red-free · L-glutamine-free |
| Storage — sterile saline | −80 °C for 18 months, or standard freezer for up to 3 months |
| Manufacturing | cGMP-aligned, sterile ISO-classified, FDA-registered U.S. facility |
| Documentation | Third-party Certificate of Analysis issued for every lot |
| Regulatory status | Research use only. Not FDA approved. |
Who BioRegenEx serves
Licensed physicians and clinics conducting research in orthopedic, aesthetic, dermatologic and other regenerative applications; independent researchers and institutions requiring characterized MSC-derived exosome material; and physician practices that need supplier documentation sufficient to satisfy their own compliance review.
BioRegenEx does not supply consumers, and material is not sold for the treatment of any disease or condition.
How the manufacturer is qualified
BioRegenEx does not run the laboratory. It qualifies the one that does, and that qualification is the product. The manufacturing partner operates a sterile, ISO-classified facility under cGMP-aligned processes consistent with 21 CFR Parts 210, 211 and 600, maintains full batch records and chain of custody for every lot, and its platform is the subject of multiple United States patent applications naming doctorate-level scientists as inventors.
The team behind the material
BioRegenEx is a small operating team rather than a sales organization, with more than five years of combined experience in regenerative medicine supply — the company grew out of an earlier operation in the same field. Individual staff names are not published; the functions, and what each is responsible for, are.
Scientific and product oversight. Reviews particle characterization and Certificate of Analysis results against specification, qualifies the manufacturing partner, and evaluates the primary literature that enters the research library.
Clinical and pharmacy oversight. Oversees handling standards, sterile technique guidance, and the storage protocols provided to partner practices.
Quality and regulatory. Manages lot release review, verification of third-party laboratory results against the Certificate of Analysis, and the regulatory language used across BioRegenEx materials.
Physician support. Handles documentation requests, onboarding, and technical questions from partner practices.
Credentials for any function are available to partner physicians on request through the Physician Portal.
Editorial standards
Educational content published by BioRegenEx — every article in the research library and every technical page on this site — is reviewed before publication for scientific accuracy and regulatory language, and to ensure that findings from preclinical models are never described as clinical outcomes. Articles carry a published date and a last-reviewed date. When the underlying evidence changes, the article changes.
What BioRegenEx does not claim
MSC-derived exosome products are not approved by the U.S. Food and Drug Administration for the treatment of any disease or condition. There are no FDA-approved exosome products of any kind. BioRegenEx material is supplied for research use only, and BioRegenEx makes no representation that it diagnoses, treats, cures, or prevents any disease.
“FDA-registered facility” means the facility is listed with the FDA as required for certain manufacturing activities. It is not an approval, a clearance, or an evaluation of any product made there. The two are routinely conflated in this category, and the conflation is usually deliberate.
This position is not a disclaimer appended to a sales page. It determines what BioRegenEx supplies, to whom, and how it is described — and any supplier telling a physician otherwise is describing a regulatory posture that does not exist.
Company facts
| Legal entity | BioRegenEx Medical Technology Corp. |
|---|---|
| Headquarters | Houston, Texas |
| Role | Distributor — not a manufacturer, not a healthcare provider |
| Operating experience | More than five years in regenerative medicine supply |
| Contact | info@bioregenex.com |
| Source tissue | Screened, consented Wharton’s Jelly (umbilical cord) |
| Lot testing | Third-party Certificate of Analysis on every lot |
| Regulatory status | Research use only. Not FDA approved. |
| Research library | 229 peer-reviewed studies, updated August 2026 |